{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T13:02:35Z","timestamp":1755694955333,"version":"3.40.5"},"reference-count":17,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Nephrology"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>COVID\u201019 remains a global pandemic with more than 10 million cases and half a million deaths worldwide. The disease manifestations in patients with chronic kidney disease and especially those on haemodialysis are still being understood, with only a few overseas case series, and small observational trials thus far. It appears that the disease is more severe in this patient cohort. Part of the pathophysiology of severe COVID\u201019 is related to accompanying cytokine release syndrome (CRS). Tocilizumab, an interleukin\u20106 inhibitor, has been trialled for treatment of CRS in COVID\u201019, but not yet approved. We present a case of an Australian patient on long\u2010term haemodialysis with severe COVID\u201019 who was successfully treated with Tocilizumab. The peak of her illness was on day 7, with a C\u2010reactive protein of 624\u2009mg\/L (reference\u2009&lt;\u20095 mg\/L), ferritin of 5293\u2009ng\/mL (reference 30\u2010500\u2009ng\/mL), and interleukin\u20106 level 1959.7 pg\/mL, consistent with CRS. She was severely hypoxic on a ventilator, with rising inotropic requirements. With the use of Tocilizumab, there was a significant and immediate response in her inflammatory markers, and she made a steady recovery. The patient was discharged home 6\u2009weeks after presentation.<\/jats:p>","DOI":"10.1111\/nep.13767","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T20:35:27Z","timestamp":1597091727000},"page":"845-849","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical benefits of Tocilizumab in <scp>COVID<\/scp>\u201019\u2010related cytokine release syndrome in a patient with end\u2010stage kidney disease on haemodialysis in Australia"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7723-3548","authenticated-orcid":false,"given":"Shiny","family":"Stephen","sequence":"first","affiliation":[{"name":"Department of General Medicine Epworth Richmond Hospital  Richmond Victoria Australia"},{"name":"Department of General Medicine Royal Melbourne Hospital  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-9306","authenticated-orcid":false,"given":"Yeung\u2010Ae","family":"Park","sequence":"additional","affiliation":[{"name":"Department of General Medicine Epworth Richmond Hospital  Richmond Victoria Australia"},{"name":"Department of General Medicine Royal Melbourne Hospital  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Chrysostomou","sequence":"additional","affiliation":[{"name":"Department of General Medicine Epworth Richmond Hospital  Richmond Victoria Australia"},{"name":"Department of Renal Medicine Epworth Richmond Hospital  Richmond Victoria Australia"},{"name":"The University of Melbourne  Parkville Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,9,17]]},"reference":[{"unstructured":"Worldometers.info. COVID\u201019 Coronavirus Pandemic Dover Delaware U.S.A.: Worldometer; 2020.https:\/\/www.worldometers.info\/coronavirus\/. Accessed 4 July 2020","key":"e_1_2_5_2_1"},{"doi-asserted-by":"publisher","key":"e_1_2_5_3_1","DOI":"10.1001\/jama.2020.2648"},{"doi-asserted-by":"publisher","key":"e_1_2_5_4_1","DOI":"10.1007\/s11255-020-02451-9"},{"doi-asserted-by":"publisher","key":"e_1_2_5_5_1","DOI":"10.1177\/2040622312466908"},{"doi-asserted-by":"publisher","key":"e_1_2_5_6_1","DOI":"10.1634\/theoncologist.2018-0028"},{"doi-asserted-by":"publisher","key":"e_1_2_5_7_1","DOI":"10.1016\/j.jtho.2020.02.010"},{"doi-asserted-by":"publisher","key":"e_1_2_5_8_1","DOI":"10.1016\/S2213-2600(20)30076-X"},{"doi-asserted-by":"publisher","key":"e_1_2_5_9_1","DOI":"10.1186\/s12967-020-02339-3"},{"doi-asserted-by":"publisher","key":"e_1_2_5_10_1","DOI":"10.1007\/s00134-020-05991-x"},{"doi-asserted-by":"publisher","key":"e_1_2_5_11_1","DOI":"10.1016\/j.autrev.2020.102568"},{"issue":"4","key":"e_1_2_5_12_1","first-page":"1","article-title":"Covid\u201019 and its impact on nephropathic patients: the experience at Ospedale \u201cGuglielmo da Saliceto\u201d in Piacenza","volume":"2","author":"Scarpioni R","year":"2020","journal-title":"G Ital Nefrol"},{"key":"e_1_2_5_13_1","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1111\/all.14238","article-title":"Clinical characteristics of 140 patients infected with SARS\u2010CoV\u20102 in Wuhan, China","volume":"75","author":"Zhang J","year":"2020","journal-title":"Eur J Allergy Clin Immunol"},{"doi-asserted-by":"publisher","key":"e_1_2_5_14_1","DOI":"10.1159\/000507305"},{"doi-asserted-by":"publisher","key":"e_1_2_5_15_1","DOI":"10.1159\/000507417"},{"key":"e_1_2_5_16_1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jgar.2020.04.024","article-title":"Continues renal replacement therapy (CRRT) with disposable hemoperfusion cartridge: a promising option for severe COVID\u201019","volume":"21","author":"Dastana F","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"doi-asserted-by":"publisher","key":"e_1_2_5_17_1","DOI":"10.1016\/S2213-2600(20)30229-0"},{"unstructured":"US National Library of Medicine. Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID\u201019 (TACOS). 2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04306705. Accessed 6 July 2020","key":"e_1_2_5_18_1"}],"container-title":["Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fnep.13767","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nep.13767","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/nep.13767","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nep.13767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T02:22:54Z","timestamp":1693880574000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/nep.13767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,17]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1111\/nep.13767"],"URL":"https:\/\/doi.org\/10.1111\/nep.13767","archive":["Portico"],"relation":{},"ISSN":["1320-5358","1440-1797"],"issn-type":[{"type":"print","value":"1320-5358"},{"type":"electronic","value":"1440-1797"}],"subject":[],"published":{"date-parts":[[2020,9,17]]},"assertion":[{"value":"2020-07-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}